RxDoctor Payments DataLook up a doctor →

Lisa Brooks, APRN

Acute Care · Chattanooga, TNNPI 1396888178

Payments from drug & device makers

$10,449in general payments, 2019–2025

Across 594 payments — averaging $17.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AbbVie$1K
  • Lilly USA, LLC$1K
  • AstraZeneca$963
  • Pfizer$649
  • Boehringer Ingelheim$433
  • plus $4K from 44 others

What the payments were for

  • Food & beverage$10,406100%
  • Education$430%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,449 in reported general payments places this provider in the 95th percentile of 738 acute care providers in Tennessee.

See all acute care providers in Tennessee

Medicare billing

Part B allowed, 2024
$90,661
Medicare patients
215
Services billed
3,204

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide90$141,255
FarxigaDapagliflozin Propanediol85$107,490
JardianceEmpagliflozin53$60,938
Trelegy ElliptaFluticasone/Umeclidin/Vilanter51$52,896
EliquisApixaban42$49,834
MounjaroTirzepatide30$43,101
RybelsusSemaglutide24$41,793
Tresiba Flextouch U-200Insulin Degludec39$40,492
MyrbetriqMirabegron40$36,430
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog29$36,380
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog32$29,823
JanuviaSitagliptin Phosphate17$28,171
XareltoRivaroxaban22$22,109
EntrestoSacubitril/Valsartan18$21,604
Tresiba Flextouch U-100Insulin Degludec14$14,780

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,730$183,048114 claims
AstraZenecaFarxiga$963$107,49085 claims
GSKTrelegy Ellipta, Breo Ellipta$220$66,06774 claims
Boehringer IngelheimJardiance$433$60,93853 claims
Lilly USA, LLCMounjaro, Trulicity$1,111$57,77646 claims
PfizerEliquis$649$49,83442 claims
Astellas Pharma US IncMyrbetriq$172$36,43040 claims
MerckJanuvia$111$28,17117 claims
Johnson & JohnsonXarelto$196$22,10922 claims
NovartisEntresto$14$21,60418 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 738 acute care providers in Tennessee.

Other acute care in Chattanooga

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →